Product Description
ORL1 antagonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23238431/)
Mechanisms of Action: MR Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cognitive Dysfunction|Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00848484 |
NCT00848484 | P2 |
Completed |
Schizophrenia|Cognitive Dysfunction |
2009-06-01 |
2022-05-04 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|